Advertisement
Advertisement
U.S. markets open in 9 hours 27 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Karolinska Development AB (publ) (0P3C.L)

LSE - LSE Delayed Price. Currency in SEK
Add to watchlist
6.50+3.87 (+147.36%)
At close: 05:40PM BST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.63
Open2.62
Bid0.00 x N/A
Ask0.00 x N/A
Day's Range2.62 - 2.62
52 Week Range2.62 - 2.62
Volume1
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)0.17
PE Ratio (TTM)7.30
EPS (TTM)0.89
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 0P3C.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Karolinska Development’s portfolio company Svenska Vaccinfabriken presents scientific advancements at international conference

      STOCKHOLM, Sweden, June 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Svenska Vaccinfabriken has presented results from a preclinical study indicating that the company’s candidate therapeutic vaccine SVF-001 has potential to elicit an immune response in a disease model of chronic hepatitis B. The results were presented on June 25 at the EASL International Liver CongressTM 2022. Svenska Vaccinfabriken develops therapeutic proteins and DNA vaccin

    • GlobeNewswire

      Karolinska Development’s portfolio company Promimic presents preclinical results showing decreased bacterial adhesion to implants

      STOCKHOLM, Sweden, June 23, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Promimic today presented preclinical results tshowing that the company’s HAnano Surface coating technology reduces the risk of adhesion by common pathogenic bacteria by up to 60%. Promimic develops and markets HAnano Surface, a unique, nanometer-thin surface treatment that aims to improve the anchorage and healing of orthopedic and dental implants into bone tissue. The techno

    • GlobeNewswire

      Karolinska Development invests in breakthrough drug project for the treatment of nerve pain

      STOCKHOLM, SWEDEN, June 3, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the company has agreed to invest SEK 20 million in PharmNovo AB, which is developing a novel drug for nerve pain, a difficult-to-treat form of pain that often develops into a chronic condition. The drug candidate PN6047 from PharmNovo has shown compelling efficacy in well-established preclinical disease models, and a first clinical trial is planned to start in late 2022. The estimated market value

    Advertisement
    Advertisement